Novel Concepts, New Perspectives, and Current Therapies for Parkinson’s Disease: 2nd Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 80
Special Issue Editor
Interests: Parkinson’s disease; therapy; drug; repurposing; novel compound; neurodegeneration; neuroinflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Parkinson’s disease (PD), the most common progressive, neurodegenerative movement disorder, is caused by a hypodopaminergic condition in the nigrostriatal system. Cardinal motor symptoms are the main determinant of the quality of life for those with PD, as well as the progression of the disability and possible nursing home placement. As life expectancy increases, the need for novel approaches to treat PD grows urgent. However, while most antiparkinsonian drugs offer symptomatic relief, they do not tackle the underlying etiology of the disease. In addition, there is currently no available therapy that slows down the progression of PD or even prevents its manifestation. The most significant limitations of approved drugs are mostly related to their side effects and lack of long-term efficacy. Therefore, driven by the increasing knowledge of neurodegeneration and neuroinflammation processes, extensive research efforts are underway to identify new strategies to modulate previously undruggable targets or to manage the disease.
The present Special Issue will highlight the state of current pharmacological strategies and explore drug candidates under treatment evaluation, as well as candidates for repurposing for the treatment of PD. Furthermore, this issue will also provide an overview of future studies and novel molecular targets that may be used to combat PD. Hence, for this Special Issue, we are inviting researchers to contribute original articles and reviews on these topics. Contributions from all research areas, including disease modeling, drug studies, and therapeutic interventions, are welcome.
I look forward to receiving your contributions.
Dr. Malgorzata Zaremba
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Parkinson’s disease
- therapy
- drug
- repurposing
- novel compound
- neurodegeneration
- neuroinflammation
